| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Showing posts with label WPA. Show all posts
Showing posts with label WPA. Show all posts
WPA IC: "PRE-CONGRESS WORKSHOPS"
WPA 2016 ISTANBUL E-BULLETIN
 | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
Congresul International al Asociatiei Mondiale de Psihiatrie 2015 in imagini | Cafe Gradiva
 | |||||||
Congresul International al Asociatiei Mondiale de Psihiatrie
Imagini de la Congresul International al Asociatiei Mondiale de Psihiatrie 2015, Bucuresti, 24-27 iunie
| |||||||
Preview by Yahoo
| |||||||
Participation in the International Congress of WFMH
Please see the letter: https://app.box.com/s/sd5yi8ku9mp5r6ue42bd
Prof. George Christodoulou
WPA Zone 9 Symposia & Workshops WPA 2013 Bucharest Congress 10-13 April 2013
Dear Jiri, Dear Colleagues of WPA Zone 9,
Greetings from DC...!
We most cordially invite you and our talented Zone 9 Psychiatric
Associations colleagues to submit your innovative ideas for symposia
and workshops at the historic WPA 2013 Bucharest Congress.
You can do so via www.wpa2013bucharest.org.
Deadline for abstracts is 10 September, 2012.
Look forward to welcoming your WPA Zone 9 delegation in beautiful
Bucharest in bloom in April 2013...!
Best,Eliot
--
Professor Eliot SOREL, MD, DLFAPA
CoChair Scientific Committee WPA 2013 Bucharest
GWU School of Medicine & School of Public Health
Founder Conflict Management Section WPA
2301 E Street, N.W., Suite # A-1011, Washington, D.C., 20037
T 202 293 2112 ; F 202 293 0440 ; M 301 254 1819
Greetings from DC...!
We most cordially invite you and our talented Zone 9 Psychiatric
Associations colleagues to submit your innovative ideas for symposia
and workshops at the historic WPA 2013 Bucharest Congress.
You can do so via www.wpa2013bucharest.org.
Deadline for abstracts is 10 September, 2012.
Look forward to welcoming your WPA Zone 9 delegation in beautiful
Bucharest in bloom in April 2013...!
Best,Eliot
--
Professor Eliot SOREL, MD, DLFAPA
CoChair Scientific Committee WPA 2013 Bucharest
GWU School of Medicine & School of Public Health
Founder Conflict Management Section WPA
2301 E Street, N.W., Suite # A-1011, Washington, D.C., 20037
T 202 293 2112 ; F 202 293 0440 ; M 301 254 1819
WPA Electronic Directory
TO WPA COMPONENTS
On behalf of Prof. Levent Küey, WPA Secretary General, please find attached a letter and two documents from the WPA Secretariat.
Best wishes,
Pamela Atiase
WPA Secretariat
World Psychiatric Association, Geneva University Psychiatric Hospital, Bâtiment Les Voirons, 2 Chemin du Petit Bel-Air, 1225 Chêne-Bourg, Geneva, Switzerland.
E-mail : wpasecretariat@wpanet.org. Tel : 4122 305 5737. Fax : 4122 305 5735. Website : www.wpanet.org.
WPA News
The December WPA News
is available online.
Read December 2009 WPA
News (pdf)
The following information is a reminder of your current mailing list subscription:
You may automatically unsubscribe from this list at any time by visiting the following URL: http://worldpsychiatricassociation.org/cgi-bin/dada/mail.cgi/u/ebulletin/
If the above URL is inoperable, make sure that you have copied the entire address. Some mail readers will wrap a long URL and thus break this automatic unsubscribe
mechanism.
You may also change your subscription by visiting this list's main screen: http://worldpsychiatricassociation.org/cgi-bin/dada/mail.cgi/list/ebulletin
If you're still having trouble, please contact the list owner at: wpasecretariat@wpanet.org
The following physical address is associated with this mailing list:
Geneva University
Psychiatric Hospital
2, ch. du Petit-Bel-Air
1225 Chêne-Bourg
Switzerland
global mental health issued by the Lancet last month. Th---------- Forwarded message ----------
From: Prof. Mario Maj <majmario@tin.it>
Date: Fri, Nov 7, 2008 at 1:20 PM
Subject:
To: aurelromila@gmail.com
From: Prof. Mario Maj <majmario@tin.it>
Date: Fri, Nov 7, 2008 at 1:20 PM
Subject:
To: aurelromila@gmail.com
From: Prof. Mario Maj [mailto:majmario@tin.it]
Sent: Friday, November 07, 2008 11:40 AM
To: abi@icc-al.org; f.kacha@caramail.com; Nstotland@psych.org;
mkalhaddad@hotmail.com; congresos@aap.org.ar; meduni@moon.yerphi.am;
secretaria@apsa.org.ar; aurelromila@gmail.com; tvoskresenski@hemo.net;
ogureje@comui.edu.ng; ulugalimov@rambler.ru; Musalek@api.or.at;
inadir@azdata.net; bap@agni.com; e.maisha@gmail.com; sobopsi@yahoo.es;
abp@abpbrasil.org.br; presidente@abpbrasil.org.br; petmarinov@abv.bg;
bpa@cervus.unibel.by; president@cpa-apc.org; zhoudf@bjmu.edu.cn;
carloslopez@une.net.co; asocopsi@cable.net.co; yosluz@yahoo.com;
hotujac@yahoo.com; psiq@hha.sld.cu; cnscs@infomed.sld.cu;
neopap@cytanet.com.cy; raboch@cesnet.cz; a.fink-jensen@dadlnet.dk;
drasolis2007@yahoo.com; josecruz@uio.satnet.net;
aokasha@internetegypt.com; lehtmets@datanet.ee; mesfinawt@yahoo.com;
jyrkor@utu.fi; Materazzi@arnet.com.ar; dr.o.schmitt@wanadoo.fr;
GibelloB@aol.com; psy-spfafp@wanadoo.fr; Nicole.Garret@wanadoo.fr;
wolfgang.gaebel@uni-duesseldorf.de; sam_ohene@yahoo.com;
emilioqb@ufm.edu.gt; psych@psych.gr; tzav3jax@otenet.gr;
costefanis@epipsi.gr; mrmndz@yahoo.com; asochondpsiq@yahoo.com;
hkcpsych@hkam.org.hk; mpt1@axelero.hu; hmagnus@landspitali.is;
info@npar.ru; roykallivayalil@dataone.in; roykalli@gmail.com;
pcs910@hotmail.com; pp_pdskji@yahoo.com; jeang.veyrat@noos.fr;
sajalili@gmail.com; muh1215@yahoo.com; bleich@post.tau.ac.il;
arsmilano@tiscalinet.it; tarpon8349@libero.it;
roger.gibson02@uwimona.edu.jm; ohmiya-kojima@khh.biglobe.ne.jp;
tdaradkh@just.edu.jo; saya_n@yahoo.com; fnjenga@africaonline.co.ke;
soochurl@snu.ac.kr; tamkad@mail.ru; sabiram@mail.ru; lpa@latnet.lv;
nabilmikati48@hotmail.com; lapnn1@yahoo.com;
algirdas.dembinskas_psichiatri@delfi.lt; jacobychr@vo.lu;
thyen@hotmail.com; jd.guelfi@ch-sainte-anne.fr;
aspsiqm@prodigy.net.mx; betiux1@hotmail.com; ayushjav@gmail.com;
injacl@cg.yu; bmf@iam.net.ma; mfbenchekroun@yahoo.fr; bmf@menara.ma;
R.Vandergaag@nvvp.net; secretariaat@nvvp.net; info@nvvp.net;
m_sanchezm@hotmail.com; jojo@sus.no; isps@isps.org;
profmrbhatti@hotmail.com; bassam_ashhab@yahoo.com; info@psipanama.org;
umaambi_papng@hotmail.com; psiquiatriaparaguaya@hotmail.com;
contacto@psiquiatriaparaguaya.org; app@speedy.com.pe;
ppa_inc@pldtdsl.net; ppa_mpocc@yahoo.com.ph; kikpsych@cm.umk.pl;
dias.cordeiro@netcabo.pt; dias.cordeiro@mail.telepac.pt;
psiqdir@huc.min-saude.pt; adrianovs@netvisao.pt; marijabl@inecco.net;
anovotni@yahoo.com; presidente@aperjrio.org.br;
fatimavvasconcellos@gmail.com; slavko.ziherl@psih-klinika.si;
upichet@medicine.psu.ac.th; tpd-myk@psikiyatri.org.tr;
drkapilnpl@hotmail.com; prelipceanudan@yahoo.com; krasnov@mtu-net.ru;
vkrasnov@rosmail.ru; vkrasnov@rosmail.ru; claudiabara_nati@yahoo.com;
msalqahtani@yahoo.com; mmadini@kfu.edu.sa; profmjg@eunet.yu;
Alex_Su@imh.com.sg; vavrusova@nspr.sk; andy.dewitte@skynet.be;
andy_de_witte@gvagroup.be; georgenaneishvili@yahoo.com;
jumavi@terra.cl; aprs@aprs.org.br; lejderman@terra.com.br;
spu@mednet.org.uy; rangaka@iafrica.com; sasop@global.co.za;
afliria@terra.es; afliria@gmail.com; jvallejo@csub.scs.es;
harisg@sltnet.lk; a_abdelrahman53@hotmail.com;
christina.spjut@comhem.se; sgpp@psychiatrie.ch; twpsyc@ms61.hinet.net;
thoret.yves@wanadoo.fr; ken.kirkby@ranzcp.org;
patopresident@rcpsych.ac.uk; essedik.jeddi@gmail.com;
peykang@superonline.com; buthosp@infocom.co.ug; inpn@ukr.net;
upa2@i.com.ua; sovepsi2007@gmail.com; numanali@hotmail.com
Cc: Pedro.Ruiz@uth.tmc.edu; kueyl@superonline.com;
akiyama@sa2.so-net.ne.jp; allan.tasman@louisville.edu;
tokasha@internetegypt.com; migueljorge@terra.com.br; Herrman H.
(h.herrman@unimelb.edu.au); Tempier R. (raymond.tempier@usask.ca);
Riba M (mriba@umich.edu); Sanchez M. (m_sanchezm@hotmail.com); Delgado
F. (fdelgado@jbgye.org.ec); Risco L. (luis.risco@gmail.com); Gask L.
(linda.gask@manchester.ac.uk); Wahlberg H. (henrik.wahlberg@sll.se);
Roca Bennasar M. (mroca@uib.es); 'Dusica Lecic Tosevski'; Soghoyan,
A.; Driss Moussaoui (psych@menara.ma); Baddoura C.
(charlesb@dm.net.lb); Adeyemi J. (jdadeyemi123@yahoo.com); Rataemane
S. (profs@mweb.co.za); Jalili S. A. (sajalili@gmail.com); Mohandas
(emohandas53@gmail.com); Shinfuku, N.; Shinfuku N.
(shinfuku@seinan-gu.ac.jp); Freidin Julian
(julian.freidin@ranzcp.org); Costa e Silva, Jorge Alberto; John Cox;
Lieh-Mak, F. (flmak@hku.hk); Prof. J.J. Lopez-Ibor;
JuanMezzich@aol.com; Prof. Dr. Ahmed Okasha;
sartorius@normansartorius.com; Costas Stefanis
(costefanis@epipsi.gr); Prof. S. Tyano; WPA Secretariat
Dear Colleagues,
I am happy to share with you a very good news.
The WPA has been invited to produce a paper for the Lancet on the
feasibility, acceptability and affordability of packages of care for
specific mental disorders across the stages of life in the various
regions of the world. All WPA Zone Representatives and Presidents of
WPA Member Societies who are interested to participate will be asked
to rate those packages of care with respect to several dimensions. A
data analysis will be made and the results will be published in the
Lancet paper. All WPA Zone Representatives and Presidents of WPA
Member Societies who have contributed will be named in the paper.
Please find below the relevant correspondence between Vikram Patel and
Richard Horton, the Lancet Editor.
I think this initiative will contribute to enhance the image of the
WPA and galvanize its components.
I look forward to hearing from you about your Society's interest to
participate. I would appreciate receiving a response by November 21.
With warmest regards,
Yours sincerely,
Mario Maj
P.S. If your Society has a new President or if you wish me to contact
another officer of your Society, please let me know.
From: Horton, Richard (ELS-CAM) [mailto:Richard.Horton@lancet.com]
Sent: Friday, November 07, 2008 7:41 AM
To: vikram.patel@lshtm.ac.uk
Cc: majmario@tin.it
Subject: Re: Proposed paper on continuum of care for mental disorders
Dear Vikram - Fabulous idea. In MNCH the continuum of care model has
had a helpful impact, so I'd be enthusiastic about developing this for
mental health.
Let's definitely add this idea to those for next year's theme issue.
My best, Richard
From: Vikram Patel [mailto:vikram.patel@lshtm.ac.uk]
Sent: Friday, November 07, 2008 4:31 AM
To: 'Horton, Richard (ELS-CAM)'
Cc: 'Prof. Mario Maj'
Subject: Proposed paper on continuum of care for mental disorders
Dear Richard
I am writing to you to inquire whether a new initiative, led by the
World Psychiatric Association, may be of relevance to the call for
papers one
WPA is the world's largest mental health organization with member
societies in nearly every country. Mario Maj, one of the most active
members of the Lancet GMH series and the new President of the WPA, has
established a new WPA Initiative on the Continuum of Care for Mental
Disorders. With me, and a small writing group, we will be carrying out
a global consultation of the nearly 200 WPA regional and country
representatives to assess the feasibilty, acceptability and
affordability of delivery mechanisms for effective interventions for
mental disorders across the life course. This approach is inspired by
the review paper in the Lancet on the continuum of care for maternal,
newborn and child health, and aims to generate (through a staged
Delphi methodology) packages of care for childhood, adolescence,
adulthood and old age, providing information on priority conditions
and delivery mechanisms in low-resource settings with a focus on
equity of coverage. This approach will complement the WHO mhGAP
initiative on development guidelines for specific mental disorders by
considering how these disorder specific packages will be delivered
across the life course, in the context of health system realities in
low-resource settings. We anticipate producing a review paper along
the lines of the maternal/newborn/child paper. Of course, we fully
understand that any paper would need to be reviewed and there is no
commitment to publish, but we are only exploring whether such a paper
may be considered for publication in the context of the call for
papers.
Regards
Vikram
Vikram Patel
Professor of International Mental Health &
Wellcome Trust Senior Clinical Research Fellow in Tropical Medicine
London School of Hygiene & Tropical Medicine
Address: Sangath Centre, Porvorim, Goa, India 403521
Fwd: advertising
From: Prof.George N. Christodoulou <gchristodoulou@ath.forthnet.gr>
Date: Mon, Nov 17, 2008 at 11:24 AM
Subject:
To: muh1215@yahoo.com, icpsych@eircom.net, irishdiv@eircom.net,
bleich@post.tau.ac.il, ableich@lev-hasharon.co.il,
arsmilano@tiscalinet.it, tarpon8349@libero.it, wdela@yahoo.com,
ohmiya-kojima@khh.biglobe.ne.jp, tdaradkh@just.edu.jo,
fnjenga@africaonline.co.ke, soochurl@snu.ac.kr, cyc@ilsanpaik.ac.kr,
tamkad@mail.ru, lpa@latnet.lv, charlesb@dm.net.lb, lapnn1@yahoo.com,
algirdas.dembinskas@mf.vu.lt, jacobychr@vo.lu, anovotni@yahoo.com,
aspsiqm@prodigy.net.mx, betiux1@hotmail.com, ayushjav@gmail.com,
injacl@cg.yu, bmf@iam.net.ma, mfbenchekroun@yahoo.fr,
drkapilnpl@hotmail.com, i.visser@adhesie.nl, P.Niesink@nvvp.net,
m_sanchezm@hotmail.com, ogureje@comui.edu.ng, jojo@sus.no,
isps@isps.org, profamalik@yahoo.com, bassam_ashhab@yahoo.com,
info@psipanama.org, ashvini_ambi@hotmail.com, spp@rieder.net.py,
app@speedy.com.pe, j_castro_m@terra.com.pe, ppa_inc@pldtdsl.net,
mariaimeld@aim.com, kikpsych@cm.umk.pl, augustynska@op.pl,
dias.cordeiro@netcabo.pt, abarbosa@netcabo.pt, avserra@fmed.uc.pt,
psiqdir@huc.min-saude.pt, adrianovs@netvisao.pt,
aurelromila@gmail.com, aurelromila@google.com,
prelipceanudan@yahoo.com, info@npar.ru, krasnov@mtu-net.ru,
vkrasnov@rosmail.ru, msalqahtani@yahoo.com, mmadini@kfu.edu.sa,
profmjg@eunet.yu, tvoskresenski@hemo.net, hong_choon_chua@imh.com.sg,
vavrusova@nspr.sk, slavko.ziherl@psih-klinika.si, sasop@global.co.za,
rangaka@iafrica.com, afliria@gmail.com, stp@stpsiq.es,
jvallejo@csub.scs.es, sep@sepsiq.es, drjmendis@yahoo.com,
a_abdelrahman53@hotmail.com, a-abdelrahman@hotmail.com,
ordforanden@svenskpsykiatri.se, christina.spjut@comhem.se,
kurt@solnet.ch, adib-essali@hotmail.com, twpsyc@ms61.hinet.net,
DAF39@tpech.gov.tw, upichet@medicine.psu.ac.th,
essedik.jeddi@gmail.com, tpd-myk@psikiyatri.org.tr,
serefozer@superonline.com, peykang@superonline.com,
buthosp@infocom.co.ug, akutikov@ukr.net, ecook@rcpsych.ac.uk,
shollins@rcpsych.ac.uk, nadast@aol.com, spu@mednet.org.uy,
ulugalimov@rambler.ru, sovepsi2007@cantv.net, sovepsi2007@gmail.com,
vantrupham53@yahoo.com
Athens, 14 November 2008
To the WPA Components
Dear Colleagues,
I am writing to invite you to the WORLD CONGRESS OF MENTAL HEALTH to
be held in Athens, Greece from 2 to 6 September 2009.
The Congress will be organized by the World Federation for Mental
Health in collaboration with the Hellenic Psychiatric Association and
the Society of Preventive Psychiatry.
I am attaching the First Announcement and Call for Abstracts and look
forward to your participation in this important event.
Yours sincerely
Prof. George Christodoulou
Congress President
August 31, 2008
Meetings of the WPA
Regions
Prague Congress Center,
September 20, 2008, 8:00 – 9:30 hours, at Club D for Region I (Americas),
Meeting Room 2.1 for Region II (Europe), Club C for Region III (Africa &
Middle East), and Terrace 1 for Region IV (Asia/Australasia)
These parallel meetings, one per Region, would include
the participation of the Zonal
Representatives and any available Member Society leaders from each of the four
WPA Regions: I.
Provisional
Agenda
|
1 |
Opening collegially by the Zonal Representatives of
the corresponding Region. |
|
2 |
Introductions of all officers
present. |
|
3 |
Review of the fulfillment of the ZRs workplans
2005-2008 |
|
4 |
Review of key WPA activities
2005- |
|
5 |
Summary report listing the meeting participants
and main conclusions, to be presented at the ensuing Board Meeting.
|
|
6 |
Adjournment |
The WPA position statement on the ethics of the use of unmodified electroconvulsive therapy
Prepared by the WPA Standing Committee on Ethics and the WPA Section of Biological Psychiatry
This position statement is an addendum to the one on the use and safety of electroconvulsive therapy that was prepared by the Section of Biological Psychiatry in 2004 and was eventually approved by the WPA General Assembly in 2005 (WPA Position Statement, 2004).
Introduction
The WPA position statement on the use and safety of ECT has referred to ethical considerations in its use; the need to obtain informed consent from those with capacity to consent; to ensure that the patients’ relatives and carers are consulted in the case of patients with impaired capacity to consent and to seek a second opinion from an appropriately trained professional. However, the statement has not dealt specifically with the use and safety of unmodified ECT or the ethics of its practice. It is to be noted in this context that most national guidelines on the use of ECT have not referred to the use of unmodified ECT. This may be related to the notion that unmodified ECT is hardly ever used in Western Europe, North America and Australasia, countries that have produced these national guidelines. The WPA, as a global health professional organisation, needs to provide guidance on the use of unmodified ECT, in view of the continued use of this method in many countries.
The use of unmodified ECT
Electroconvulsive therapy, which was introduced in 1938, was originally unmodified and involved the administration of electrical current resulting in a generalised convulsion. Injuries resulting from violent convulsions were prevented by applying physical restraint and holding of the patient. ECT induces a central seizure detected by eletroencephalogram and a visible convulsion. All along, it was conceived that the central seizure and the peripheral convulsion were the effective ingredients in ECT. The ECT procedure was modified in the 1950s with the introduction of anaesthesia and muscle relaxation prior to the administration of ECT. In addition, patients were premedicated with atropine, administered subcutaneously 30-60 minutes before the ECT, to reduce bronchial secretions and inhibit the vagal discharge which accompanies the convulsion and thus minimise the occurrence of arrhythmias. In view of the cerebral effects of atropine it was later replaced by methylscopolamine, which does not cross the blood-brain barrier.
For anaesthesia, short acting barbiturates such as methylhexitone or thyopentone are used at the minimal dose so that the seizure threshold is not raised. The dose should be sufficient to induce unconsciousness to prevent the terrifying experience of total paralysis, including paralysis of respiratory muscles, induced by the muscle relaxant.
Once the patient is rendered unconscious, the muscle relaxant (suxamethonium), the modifying agent with the effect of abolishing the peripheral convulsion, is introduced. Once the anaesthetic and the muscle relaxant are given, 100% oxygen is administered by mask before and after the convulsion and continued until spontaneous respiration has returned. The safe administration of ECT requires the involvement of an anaesthetist or other appropriately trained health practitioners such as psychiatrists or nurses.
Current use of unmodified ECT
The use of unmodified ECT has been variously described as barbaric, inhumane and unethical, labels that have also been used to describe ECT whether modified or unmodified. In the case of unmodified ECT, this derives from the impression of the onlookers witnessing the patient whilst having a generalised convulsion and being physically held and restrained to prevent physical injury. With the introduction of modified ECT, in the 1950s, the use of unmodified ECT was gradually phased out over the next two decades. Modified ECT has become the standard practice in Western Europe, North America and Australasia. However, reports and surveys have shown that unmodified ECT is still used in Japan, Russia,
* Our Turkish colleagues have reassured us that administration of unmodified ECT has ceased now.
China, India, Thailand , Turkey* and in many low and middle – income countries.
Concerns were expressed by the European Committee for the Prevention of Torture and Inhuman or Degrading Treatment or Punishment on the use of unmodified ECT in Turkey (http://www.cpt.coe.int/en/states/tur.htm). The Turkish Government has responded to the report indicating that it has taken corrective action (http://www.cpt.coe.int/documents/tur/2006-30-inf-eng.htm).
A recent survey of ECT practice in Japan reported the use of unmodified ECT in 60 institutions (Chanpattana, et al, 2005) and in 37 of these 60 institutions unmodified ECT was used exclusively, less in University than in non – University psychiatric hospitals. The reasons for using unmodified ECT included emergency, lack of anaesthetist and equipment, being “safer than modified ECT” and being reserved for young people. Particular side - effects of unmodified ECT included incidence of teeth injury, arrthymia and fracture/dislocation. No cases of ECT – related death were reported.
A national survey of ECT use in the Russian Federation reported that fewer than 20% of ECTs were modified with anaesthesia. Anaesthesia and muscle relaxants were never used in 31 out of the 42 responding institutions, estimating that 21% of institutions used modified ECT at least sometimes (Nelson, 2005). It was noted in the report that there was no system or expectation for ECT training and no national organisation to advance ECT practice despite the respondents’ enthusiasm and positive attitudes towards ECT and for adopting modern ECT methods.
The national Survey of ECT Practice in Thailand (Chanpattana and Kramer, 2004) showed that unmodified ECT was used always in 9 psychiatric and 5 general hospitals and occasionally in two university hospitals, comprising 94% of all ECT use. Respondents gave reasons for their use of unmodified ECT: lack of funds, convenience, lack of personnel, lack of equipment, lack of anaesthesia and economic reasons. This was related to the poor infrastructure and resourcing of mental health services and specifically to the psychiatrists’ attitudes and lack of training in the practice of ECT.
A survey of the practice of ECT in 188 teaching institutions and psychiatric hospitals in India, showed that more than 70% of ECT administrations were performed in psychiatric hospitals and approximately half of ECT use was on unmodified ECT (Chanpattana et al, 2005).
However, there are very few reports on the use of unmodified ECT from low income countries, except for earlier studies from Nigeria indicating that unmodified ECT was the main method of administration (Obejide et al, 1987; Ikeji et al, 1999). This is likely to be the case in many low income countries, in view of the poor infrastructure and funding for psychiatric services and the lack of trained mental health professionals.
The efficacy and safety of unmodified ECT
There have been few controlled studies on the comparative efficacy of modified and unmodified ECT. Kendell (1981) reviewed the few controlled studies and concluded that modified and unmodified ECT were equally effective, as shown in the studies by Havens (1958) and Seager (1959) which both involved substantial numbers of patients who were randomly allocated to the two treatments. Further studies specifically evaluating the therapeutic effects of the convulsion confirmed it as the therapeutic ingredient (Ulett et al, 1956; Laurell, 1970; Ottosson, 1960). The role of the convulsion in mediating the therapeutic effects of ECT has, of course, been strongly supported by the controlled studies of real and simulated ECT reviewed in the WPA consensus statement on its use (2004).
The controversy over the use of unmodified ECT, however, has been mainly related to its risks and adverse effects. Not withstanding the recognised and well documented adverse effects of ECT, as reviewed in the WPA consensus statement, unmodified ECT has been associated with physical injuries produced by the uncontrolled convulsive movements which cause fractures in the mid thoracic vertebrae and dislocations particularly of the jaw, occurring in 30% of patients in some studies (Kendell, 1981). Andrade et al (2003) highlighted the disadvantages of unmodified ECT with reference to Western research conducted in the 1940s and 1950s which suggested that convulsions were associated with 20-40% risk of multiple subclinical vertebral body compression fractures, mostly affecting the middle thoracic vertebrae, observed mainly in males, in young and in old subjects. However, these fractures were not associated with pain or other symptoms and did not require orthopaedic intervention.
Andrade et al (2003) have reported new research on the adverse effects of unmodified ECT conducted in India between 1980 and 1990, reporting that only 0.7 % of patients had fractures with unmodified ECT, the majority of whom suffered no pain or disability or other musculoskeletal complications (Tharyan et al, 1993). A further study with radiological evidence showed 2% rate of vertebral injury (Andrade, et al, 2000). Unmodified ECT does not appear to cause internal tissue damage (Ohaeri et al, 1992).
It must be noted that unmodified ECT is essentially unmonitored ECT as well, meaning that all acquired knowledge as to the monitoring of the seizure and the related physiological parameters can not be used.
Ethical considerations
The principal ethical concern about the use of unmodified ECT is related to the risk of suffering the aforementioned adverse effects that do not occur when modified ECT is used. However, such risks should be set against the benefits of administration of unmodified ECT in cases where ECT is strongly indicated and can not be given in its modified form. Such a case is psychotic depression with high suicidal risk which requires rapid intervention with ECT, the most effective treatment in such a condition.
The pros and cons of administering unmodified ECT should be carefully considered. In any case, however, informed consent, including consent of the patient’s relatives and carers, should be secured. There needs to be an appreciation of the realities of practice of ECT in low income countries with poor service infrastructure and limited availability of anaesthetists and medication for the administration of modified ECT. It must be noted that there is no guidance on the use of unmodified ECT by the American Psychiatric Association, the Royal College of Psychiatrists and other authoritative bodies catering for ECT practice in high income and well resourced countries. The WPA as a global association of national psychiatric organisations strongly advocates the use of modified ECT as standard and optimal practice. However, it is recognised that there are cases in which psychiatrists are faced with the situation where ECT is strongly indicated but there are no facilities and skilled staff to administer it in its modified form. In these cases, unmodified ECT should be considered as an option after full consultation with the patients and their relatives and ensuring informed consent is obtained. Such considerations are no different from considerations of urgent medical and surgical interventions that may be associated with greater risks and more serious adverse effects.
Andrade et al (2003) in their commentary on the dilemma of unmodified ECT, referred to the civil rights activities in India which culminated in a non - governmental organisation for the rights of the mentally ill filing a petition to the supreme court of India in 2001 seeking a blanket prohibition of the practice of unmodified ECT. In relation to this, it is noted that the national psychiatric associations in India have advocated that, whilst the practice of modified ECT should be the rule, consideration should be given to exceptions when unmodified ECT should be considered. The verdict of the Supreme Court is still awaited. Andrade et al (2003) regretted that the Indian Psychiatric Society had not taken an official position on the use of unmodified ECT or produced guidelines to that effect and have advocated that “there are extenuating circumstances in which unmodified ECT may be better than no ECT …. and that the decision to administer unmodified ECT must be made in exceptional circumstances and on a case by case basis, and never as a routine practice …… “
Conclusions and Recommendations
Whilst unmodified ECT is as effective as modified ECT (administered with an anaesthetic and a muscle relaxant) it is associated with significant risk and adverse effects (fractures and dislocation) and with pre-treatment suffering of the patient which do not occur with modified ECT. This has rendered the use of unmodified ECT more controversial than modified ECT and raised ethical concerns over its continued use. Recent reviews of the practice of ECT have indicated that unmodified ECT is still in use in countries, mainly developing and of low income, with poor infrastructure and funding for mental health services and limited professional human resources. Understandably, guidances from National Professional Associations in Western Europe and the US have not tackled the issue of the use of unmodified ECT as it is no longer in use in these countries.
Regrettably the national psychiatric associations in countries where unmodified ECT is still in use, have not provided guidance on its use. The WPA, as a global professional association and following the International congress in Istanbul (2006) and the ECT Instanbul consensus Recommendations (2006) has issued this addendum statement on the use, safety and ethics of unmodified ECT and makes the following recommendations:
The National Member Societies of the WPA, in collaboration with their governments are asked to implement the WPA declarations, statements and guidelines on ethics and consider the recommendations of the WHO resource book on mental health, human rights and legislation, with the following aims:-
- To support ethical practices and observe human rights in all clinical, research, educational and policy activities;
- To implement modified ECT as standard practice for every person who needs this treatment.
· To cease the use of unmodified ECT, in view of evidence indicating that this method has no difference in effectiveness from modified ECT but has more adverse effects.
- In settings where the current choice in the field is unmodified ECT or no ECT, to make decisions on the basis of the clinical condition of the patient, current evidence - based information, the informed consent of patient and relatives and the consideration of possible, equally effective alternative treatments.
- To urgently make every effort for the creation of the necessary infrastructure for the provision of modified ECT. This is an ethical obligation on the part of Governments, professional organizations and individual practitioners. In countries where this infrastructure exists, there is no excuse for the administration of unmodified ECT.
References
Andrade, C., Rele, K., Sutharshan, R., Shah, N. (2000) Musculoskeletal morbidity with unmodified ECT may be less than earlier believed. Indian Journal of Psychiatry, 42: 156-162.
Andrade C. (2003) Unmodified ECT: ethical issues. Issues Med Ethics, 11(1): 9-10.
Andrade C, Shah N, & Tharvan, P. (2003) The dilemma of unmodified electroconvulsive therapy. Journal of Clinical Psychiatry, 64 (10); 1147-1152.
APA BOT Statement on the use of unmodified ECT, adopted in March 2007.
Chanpattana W, and Kramer BA, (2004) Electroconvulsive therapy practice in Thailand. J ECT, 20 (2): 94-98.
Chanpattana W, Kojima K, Kramer BA, Intakorn A, Sasaki S, Kitphati R. (2005) ECT practice in Japan. J ECT, 21 (3): 139-144.
Chanpattana W, Kunigiri G, Kramer BA, Gangadhar BN. (2005)
Survey of the practice of electroconvulsive therapy in teaching hospitals in India. J ECT. 2005 Jun;21(2):100-4.
ECT Instanbul Consensus Recommendations (prepared by C. Yazgan, R. Okin, Th. Bolwig, O. Steenfeldt-Foss, D. Yesibursa, J. McIntyre, S. Rataemane and E. Sorel) 2006.
Havens L. L. (1958) A comparative study of modified and unmodified electric shock treatment. Diseases of the Nervous System, 19: 1-6.
Ikeji OC, Ohaeri JU, Osahon RO, Agidee RO. (1999). Naturalistic comparative study of outcome and cognitive effects of unmodified electro-convulsive therapy in schizophrenia, mania and severe depression in Nigeria. East Africa Med J.;76(11):644-50.
Kendell, R. E. (1981) The present status of electroconvulsive therapy. British Journal of Psychiatry, 139: 265-283.
Laurell, B. (1970) Flurothyl convulsive therapy. Acta Psychiatrica Scandinavica, Suppl. 213.
Nelson, A. I. (2005) A national survey of electroconvulsive therapy use in the Russian Federation. J ECT, 21 (3): 151-157.
Odejide AO, Ohaeri JU, Ikuesan BA. (1987). Electroconvulsive Therapy in Nigeria. Convuls Ther. 1987;3(1):31-39
Ohaeri, J. U., Hedo, C. C., Envidah, S. N., Ogunnivi, A. O. (1992) Tissue injury inducing potential of unmodified ECT: serial measurement of acute phase reactants. Convuls. Therapy, 8 (4): 253-257.
Ottosson, J.O. (1960) Experimental studies of the mode of action of electroconvulsive therapy. Acta Psychiatrica Scandinavica, Suppl. 145.
Seager, C. P. (1959) Controlled trial of straight and modified electroplexy. Journal of Mental Science, 105: 1022-1028.
Tharyan, P., Saju, PJ., Datta, S., John, JK., Kuruvilla, K. (1993) Physical morbidity with unmodified ECT: a decade of experience. Indian Journal of Psychiatry, 35: 211-214.
Ulett, G. A., Smith, K. and Gleser, G. C. (1956) Evaluation of convulsive and subconvulsive shock therapies utilizing a control group. American Journal of Psychiatry, 112: 795-802.
WPA position statement on the use and safety of ECT (2004) Science and Care, Bulletin of the WPA Scientific Sections,1:7-11.
This statement was prepared my Mohammed Abou Saleh, it has been revised and edited by George Christodoulou, has been reviewed by the members of the WPA Standing Committee on Ethics and the WPA Section of Biological Psychiatry and has incorporated the comments of the WPA Member Societies and other WPA components. Special mention must be made of the contribution of Eliot Sorel and the WPA Section on Conflict Management and Resolution.
Submitted in August 2008
On behalf of the WPA Standing Committee on Ethics
Prof George Christodoulou
On behalf of the WPA Section on Biological Psychiatry
Prof Mohammed Abou-Saleh
Subscribe to:
Posts (Atom)